Intelligent Bio Solutions Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The filing, an Amendment No. 1 to Statement on Schedule 13G, indicates that Ionic Ventures LLC, Ionic Management LLC, and individuals Keith Coulston and Brendan O’Neil, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of the company's outstanding common stock. This amendment serves as an exit filing for the Reporting Persons. The shares in question, totaling 112,803, represent 4.9% of the company's class of securities after accounting for a one-for-12 reverse stock split effected on January 26, 2024. The Reporting Persons had entered into a Joint Filing Agreement...Show More

Intelligent Bio Solutions Inc. has been the subject of an amended filing with the U.S. Securities and Exchange Commission (SEC) on February 14, 2024. The filing, an Amendment No. 1 to Statement on Schedule 13G, indicates that Ionic Ventures LLC, Ionic Management LLC, and individuals Keith Coulston and Brendan O’Neil, collectively referred to as the Reporting Persons, have ceased to be the beneficial owners of more than five percent of the company's outstanding common stock. This amendment serves as an exit filing for the Reporting Persons. The shares in question, totaling 112,803, represent 4.9% of the company's class of securities after accounting for a one-for-12 reverse stock split effected on January 26, 2024. The Reporting Persons had entered into a Joint Filing Agreement to file this amendment jointly in accordance with SEC regulations. The filing also notes that the shares of common stock reported are based on 2,147,789 outstanding shares as disclosed in the company's Quarterly Report on Form 10-Q for the period ended December 31, 2023, and do not fully account for shares issuable upon the exercise of Series G warrants subject to a beneficial ownership blocker.